Analysis of implementation status and effectiveness of treatments in the Chinese diagnosis and treatment recommendation for COVID-19 at local hospitals: Recommendation for COVID-19 at local hospitals

Han Liu; Jing Jie; Jingjing Luo; Liping Peng; Shucheng Hua; Lei Song; Dan Li

doi:10.54844/cai.2022.0071

Authors

Han Liu Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Jing Jie Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Jingjing Luo Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Liping Peng Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Shucheng Hua Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Lei Song Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Dan Li Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun 130061, Jilin Province, China

DOI:

https://doi.org/10.54844/cai.2022.0071

Keywords:

Coronavirus disease 2019, recommendation, implementation status, antiviral treatment, steroids

Abstract

Background: Since the outbreak of coronavirus disease 2019 (COVID-19), China updated a total of seven editions of the official guidelines. We analyzed the treatment of patients to understand how the several editions of diagnosis and treatment recommendation guided the local medical institutions from a regional perspective. Methods: This study included a total of 93 patients who were suspected or confirmed cases of COVID-19. We analyzed the use of antiviral treatments, antibiotics, steroid, and life support measures in these patients. Based on the time of admission and the update of the official recommendations, we compared the treatments complied with the updated versions of the diagnosis and treatment recommendation. Results: All the 93 cases received different types of antiviral drugs. There were 41 cases of the use of antiviral drugs did not comply with the recommendations. There were 82 cases who received antibiotics, and 31 cases did not comply with the recommendations. 53 patients who received steroids, but only 3 patients comply with the recommendations. One patient was treated with extracorporeal membrane oxygenation (ECMO), but the timing was delayed compared with the recommendations. 91 patients were cured and discharged, one died, and one was still treated in hospital for other diseases after being tested negative. Conclusions: The antiviral treatment initially involved too many types of drugs, and the duration of medication was too long. There was also an overuse of antibiotics. In addition, the use of steroids did not comply with the recommendations. The timing of intubation for mechanical ventilation and the timing of using ECMO were more conservative.

References

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 1st edition). 2020. Available at: https://www.cn-healthcare.com/articlewm/20200121/content-1083494.html. Accessed on January 16, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 2nd edition). 2020. Available at: http://xajdyfytsg.superlib.libsou.com/info/71527.jspx. Accessed on January 18, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 3rd edition). 2020. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml. Accessed on January 23, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 4th edition). 2020. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml. Accessed on January 27, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 5th edition). 2020. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml. Accessed on February 4, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 6th edition). 2020. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Accessed on February 18, 2020.

National Health Commission and National Administrative Office of Chinese Tradition Medicine. Chinese Diagnosis and Treatment Recommendation for COVID-19 (the 7th edition). 2020. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. Accessed on March 3, 2020.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–1720. DOI: https://doi.org/10.1056/NEJMoa2002032

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199–1207. DOI: https://doi.org/10.1056/NEJMoa2001316

Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020;12:135. DOI: https://doi.org/10.3390/v12020135

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061–1069. DOI: https://doi.org/10.1001/jama.2020.1585

Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and Coronaviruses. Viruses 2019;11:41. DOI: https://doi.org/10.3390/v11010041

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105924

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020;92:479–490. DOI: https://doi.org/10.1002/jmv.25707

Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol 2014;88:5209–5212. DOI: https://doi.org/10.1128/JVI.03488-13

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. 2020. Available at: https://med.ckcest.cn/details.html?id=4895533089228800&classesEn=report. Accessed on March 13, 2020. DOI: https://doi.org/10.15557/PiMR.2020.0003

Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020;80:401–406. DOI: https://doi.org/10.1016/j.jinf.2020.02.018

Song X, Liu X, Wang C. The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province. Crit Care 2020;24:178. DOI: https://doi.org/10.1186/s13054-020-02884-9

Zhang Y, Ma ZF. Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among Local Residents in Liaoning Province, China: A Cross-Sectional Study. Int J Environ Res Public Health 2020;17:2381. DOI: https://doi.org/10.3390/ijerph17072381

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–475. DOI: https://doi.org/10.1016/S0140-6736(20)30317-2

Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683–684. DOI: https://doi.org/10.1016/S0140-6736(20)30361-5

Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006;129:1441–1452. DOI: https://doi.org/10.1378/chest.129.6.1441

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934–943. DOI: https://doi.org/10.1001/jamainternmed.2020.0994

Sarkar S, Khanna P, Soni KD. Are the steroids a blanket solution for COVID-19? A systematic review and meta-analysis. J Med Virol 2021;93:1538–1547. DOI: https://doi.org/10.1002/jmv.26483

Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID‐19): challenges and recommendations. Lancet Respir Med 2020;8:506–517. DOI: https://doi.org/10.1016/S2213-2600(20)30161-2

Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents 2020;55:105944. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105944

Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med 2020;201:1372–1379. DOI: https://doi.org/10.1164/rccm.202003-0543OC

Willyard C. The drug‐resistant bacteria that pose the greatest health threats. Nature 2017;543:15. DOI: https://doi.org/10.1038/nature.2017.21550